School of Medicine
Showing 151-170 of 170 Results
-
David K. Stevenson, M.D.
Harold K. Faber Professor of Pediatrics and Professor, by courtesy, of Obstetrics and Gynecology and of Anesthesiology, Perioperative and Pain Medicine
On Partial Leave from 09/01/2024 To 08/31/2025Current Research and Scholarly InterestsOur research is focused on the study of the ontogeny and control of heme catabolism and bilirubin production in the developing neonate. A better understanding of the role of increased bilirubin production in neonatal jaundice and the prevention of hemolytic jaundice has remained an overall objective of our program. We are also study the causes of preterm birth and ways to prevent it.
-
George F Tidmarsh
Adjunct Professor, Pediatrics - Neonatology
BioDr. Tidmarsh received M.D. and Ph.D. from Stanford University, where he also completed fellowship training in Pediatric Oncology and Neonatology and is currently Adjunct Faculty of Pediatrics and Neonatology. He served as clinical faculty at Stanford for a number of years after fellowship prior to devoting his full time to clinical research and development in order to bring new treatments through the FDA approval process. Dr. Tidmarsh was President, Chief Executive Officer, Secretary and a Director of La Jolla Pharmaceutical Company from January 2012 until November 2019. While at La Jolla, Dr. Tidmarsh helped discover the use of angiotensin II for the treatment of shock and led all aspects of the development including approval by the US FDA and the EMA for the treatment of patients suffering from distributive shock. He also led the development of artesunate for the treatment of severe malaria, now pending action for potential approval at the FDA. Dr. Tidmarsh has over 30 years of experience in biotechnology, including the successful clinical development of three FDA-approved drugs. He previously served as the Chief Executive Officer of Horizon Pharma, Inc., a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of rheumatoid arthritis. He also founded Threshold Pharmaceuticals, Inc. and held senior positions at Coulter Pharmaceutical, Inc. (acquired by GlaxoSmithKline) and SEQUUS Pharmaceuticals, Inc. (acquired by Johnson & Johnson). While at Coulter and SEQUUS, Dr. Tidmarsh led the clinical development of BEXXAR and Doxil, respectively, two FDA-approved anti-cancer agents.
At Stanford, Dr. Tidmarsh is devoted to teaching clinical research and development to residents, fellows and junior faculty. In addition, he is working to help improve the quality of medical care through various efforts which include serving on the board of Lucile Packard Foundation for Children's Health. -
Paul H. Wise, MD, MPH
Richard E. Behrman, MD, Professor of Child Health and Society, Professor of Health Policy and Senior Fellow at the Freeman Spogli Institute for International Studies
On Leave from 02/01/2024 To 12/20/2024Current Research and Scholarly InterestsHe is a health policy and outcomes researcher whose work has focused on children's health; health-outcomes disparities by race, ethnicity and socioeconomic status; the interaction of genetics and the environment as these factors influence child and maternal health; and the impact of medical technology on disparities in health outcomes.
-
Jadene Wong
Clinical Associate Professor, Pediatrics - Neonatal and Developmental Medicine
Clinical Associate Professor, Pediatrics - General PediatricsCurrent Research and Scholarly Interests- Care of the Infant with Neonatal Opioid Withdrawal Syndrome (NOWS)
https://www.cpqcc.org/resources/neonatal-opioid-withdrawal-syndrome-nows-toolkit
https://nastoolkit.org/
https://podcasts.apple.com/us/podcast/episode-17-neonatal-abstinence-syndrome-dr-jadene-wong/id1581530231?i=1000558004429
- Primary Care for Preterm Infants and Children
https://www.cpqcc.org/preterm-primary-care-toolkit -
Ronald J. Wong
Sr Res Scientist-Basic Ls, Pediatrics - Neonatology
Current Role at StanfordSenior Research Scientist